Participants
ALBI, HCC
LIVER CANCER, DISEASE CHARACTERISTIC, ONCOLOGY
From March 2018 to March 2019, 47 patients with advanced HCC and 51 healthy volunteers were enrolled in parts 1 and 2 of the study (Figure The study population comprised 66 patients and 51 healthy volunteers, who all underwent at least one AutEMdev exposure procedure (Figure Baseline demographics and disease characteristics.Abbreviations: ALBI, albumin–bilirubin; BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; NA, not available; TKI, tyrosine kinase inhibitor.Missing in one patient.Patients may have received more than one concurrent treatment during the study.See Table Three patients received standard treatment during follow‐up but were included in the monotherapy group.